Trial IMA401-101

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

IMA401-101

Full title

A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients with Recurrent and/or Refractory Solid Tumors

NCT number

NCT05359445

Responsible organization

3. Med 3. Med Ismaninger Str. 22 81675 München Germany

Indications

Classification	Code	Description
-		Other tumors

Trial design

Phase

Status

Recruitment active

Votes

Initiiation & lock

Date of lock (planned / actual)

Unknown / Unknown

Therapy

Zielgerichtet

Participants

	Function	Prename	Surname	Organization
	Responsible contact	Judith	Hecker	3. Med 3. Med Ismaninger Str. 22 81675 München Germany